Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive Dengue Antiviral Platform Trial (ADAPT): a Phase 2 Randomized, Adaptive, Open Label Trial for Antiviral Screening in Patients With Early Symptomatic Dengue

NCT06551844 is registered in ClinicalTrials.gov with Oxford University Clinical Research Unit, Vietnam as lead sponsor.

NCT NCT06551844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06551844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive Dengue Antiviral Platform Trial (ADAPT): a Phase 2 Randomized, Adaptive, Open Label Trial for Antiviral Screening in Patients With Early Symptomatic Dengue
Lead sponsor
Oxford University Clinical Research Unit, Vietnam
Phase
Phase 2
Overall status
Recruiting
Start date
April 20, 2026
Completion date
December 31, 2030
Enrollment
500 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

antiviral drugs, dengue